Mineralys Therapeutics (MLYS) Cash from Financing Activities (2022 - 2026)

Mineralys Therapeutics has disclosed Cash from Financing Activities across 5 years of filings, most recently posting $24.3 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $24.3 million, down 87.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $426.0 million (up 125.14% YoY), and the FY2025 annual result was $591.0 million, up 408.86% from the prior year.
• Cash from Financing Activities came in at $24.3 million for Q1 2026 at Mineralys Therapeutics, down from $96.7 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $295.2 million in Q3 2025 to a low of -$1.1 million in Q4 2022.
• The 5-year median for Cash from Financing Activities is $9.8 million (2025), against an average of $62.5 million.
• Across the five-year window, Cash from Financing Activities slumped 100.54% in 2024 and surged 29518900.0% in 2025, its largest moves.
• Mineralys Therapeutics' Cash from Financing Activities stood at -$1.1 million in 2022, then soared by 106.93% to $74000.0 in 2023, then increased by 21.62% to $90000.0 in 2024, then surged by 107345.56% to $96.7 million in 2025, then sank by 74.9% to $24.3 million in 2026.
• The last three Cash from Financing Activities figures came in at $24.3 million (Q1 2026), $96.7 million (Q4 2025), and $295.2 million (Q3 2025), per Business Quant data.